Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 364

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Squamous cell carcinoma of lung

Not yet recruiting

Study of Cemiplimab, Platinum and Gemcitabine in Treatment‑Naïve Patients with Advanced Squamous Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cemiplimab

Myeloproliferative neoplasm

Not yet recruiting

Anakinra for patients with myeloproliferative neoplasms resistant to cytoreductive therapy: a study to improve treatment response

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra

Pituitary tumour benign

Not yet recruiting

Fluoroethyltyrosine F-18 PET Scan for Adults with Suspected Functional Pituitary Adenoma and Unclear MRI Results

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluoroethyltyrosine F-18

Non-small cell lung cancer stage III

Not yet recruiting

Durvalumab personalized consolidation immunotherapy after chemoradiotherapy in patients with stage III non‑small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Migraine without aura

Not yet recruiting

Study of apremilast‑induced headache and migraine in women with migraine without aura

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Apremilast

Cardiogenic shock

Not yet recruiting

High-dose insulin lispro, potassium chloride and glucose treatment for patients with non‑toxic acute cardiogenic shock

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Glucose

Neoplasm

Not yet recruiting

Study of IDE849, IDE‑161 and durvalumab evaluating safety and efficacy in patients with DLL3‑positive tumors including small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Psychotic disorder+2

Not yet recruiting

A Randomized Controlled Trial of Cannabidiol vs Placebo Augmentation in Patients with First Episode Psychosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Cannabidiol

Endocarditis bacterial

Not yet recruiting

Dalbavancin versus standard drug combination for treatment of infective endocarditis caused by Gram‑positive cocci in adult patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin

Infertility+2

Not yet recruiting

Micronised progesterone luteal-phase support improves live birth rates in women with unexplained infertility

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Progesterone, Micronised

Severe myoclonic epilepsy of infancy

Not yet recruiting

Safety and Tolerability of Intrathecal ION337 in Patients with Dravet Syndrome

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years

Neoplasm+1

Not yet recruiting

Safety and Tolerability of Inhaled KB707 with or without Docetaxel in Patients with Advanced Lung Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.